Q32 Bio Inc. (QTTB)
QTTB Stock Price Chart
Explore Q32 Bio Inc. interactive price chart. Choose custom timeframes to analyze QTTB price movements and trends.
QTTB Company Profile
Discover essential business fundamentals and corporate details for Q32 Bio Inc. (QTTB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
28 Mar 2018
Employees
28.00
Website
https://www.q32bio.comCEO
Jodie Pope Morrison
Description
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
QTTB Financial Timeline
Browse a chronological timeline of Q32 Bio Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is -$0.53, while revenue estimate is $1.00m.
Earnings released on 5 May 2026
EPS came in at -$0.54 surpassing the estimated -$0.68 by +20.59%.
Earnings released on 10 Mar 2026
EPS came in at $3.65 surpassing the estimated -$0.85 by +529.41%, while revenue for the quarter reached $53.74m , meeting expectations.
Earnings released on 13 Nov 2025
EPS came in at -$0.60 surpassing the estimated -$1.39 by +56.83%.
Earnings released on 6 Aug 2025
EPS came in at -$0.78 surpassing the estimated -$1.14 by +31.58%.
Earnings released on 8 May 2025
EPS came in at -$0.90 surpassing the estimated -$1.23 by +26.83%.
Earnings released on 11 Mar 2025
EPS came in at -$1.16 surpassing the estimated -$1.25 by +7.20%.
Earnings released on 7 Nov 2024
EPS came in at -$1.46 falling short of the estimated -$1.41 by -3.55%.
Earnings released on 8 Aug 2024
EPS came in at -$1.42 falling short of the estimated -$1.00 by -42.00%.
Earnings released on 9 May 2024
EPS came in at -$13.15 falling short of the estimated -$1.42 by -826.06%.
Stock split effective on 26 Mar 2024
Shares were split 1 : 18 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 Mar 2024
EPS came in at -$0.28 surpassing the estimated -$0.30 by +6.67%, while revenue for the quarter reached -$14.66m , missing expectations by -3.03k%.
Earnings released on 14 Nov 2023
EPS came in at -$0.57 falling short of the estimated -$0.42 by -35.71%, while revenue for the quarter reached $1.86m , beating expectations by +271.80%.
Earnings released on 27 Jul 2023
EPS came in at -$10.98 falling short of the estimated -$8.55 by -28.42%, while revenue for the quarter reached $354.00k , missing expectations by -57.38%.
Earnings released on 30 Mar 2023
EPS came in at -$9.00 surpassing the estimated -$9.54 by +5.71%, while revenue for the quarter reached $802.00k , missing expectations by -20.95%.
Earnings released on 30 Dec 2022
EPS came in at -$10.74 falling short of the estimated -$8.86 by -21.21%, while revenue for the quarter reached $802.00k , missing expectations by -3.44%.
Earnings released on 29 Sept 2022
EPS came in at -$10.57 falling short of the estimated -$8.21 by -28.64%, while revenue for the quarter reached $802.00k , missing expectations by -6.81%.
Earnings released on 29 Jun 2022
EPS came in at -$9.12 surpassing the estimated -$9.68 by +5.70%, while revenue for the quarter reached $802.00k , missing expectations by -19.88%.
Earnings released on 30 Mar 2022
EPS came in at $28.65 , while revenue for the quarter reached $802.00k .
Earnings released on 30 Dec 2021
EPS came in at -$10.58 falling short of the estimated -$8.87 by -19.28%, while revenue for the quarter reached $802.00k , missing expectations by -88.87%.
Earnings released on 29 Sept 2021
EPS came in at -$9.65 , while revenue for the quarter reached $1.68m .
QTTB Stock Performance
Access detailed QTTB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
